Movement Alert|Recursion Pharmaceuticals, Inc. falls 5.33% in Regular Trading, market continues to reassess REC-4881 registrational trial path after data-driven rally fades

Market Focus00:43

On November 18, Recursion Pharmaceuticals, Inc. fell 5.33% in Regular Trading, trading at $2.7501 per share, with turnover of $21.9626 million.

The clearest catalyst in recent market updates is that enthusiasm following the company’s REC-4881 Phase 2 data update has continued to fade, with investors refocusing on the timing and prospects of a registrational trial and the scope for valuation recovery.

Recent disclosures said updated TUPELO Phase 1b/2 data showed REC-4881 delivered deep and durable reductions in polyp burden in familial adenomatous polyposis, with a relatively clean safety profile that supports advancing toward a registrational study. Separately, third-quarter revenue was $18.552 million, above the $14.783 million consensus estimate, while EPS was a loss of $0.22, in line with expectations. The company also previously raised about $200 million through a stock offering and disclosed a $10 million milestone tied to Sanofi’s optioning of a collaboration candidate, providing additional business context but not altering the market’s current focus on REC-4881 execution.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment